Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has worked faithfully but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as being a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. My first CytoDyn article, “CytoDyn: What In order to Do When It’s Too Good to be able to Be True?”, set away the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan offered such a highly marketing picture in the Uptick Newswire interview which I came away with an inadequate impression of the business.

Irony of irony, the bad opinion of mine of the business has grown steadily, yet the disappointment has not been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein is the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall mean as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and also associated intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and also the first new drug application approval ($5 million), as well as royalty payments of five % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many indications and many therapies, it’s this individual therapies as well as a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely beneficial therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic organization with diverse interests albeit focused on leronlimab, several illness types, multiple publications in addition to multiple presentations.

Could all of it be smoke cigarettes and mirrors? That is a question I have been asking myself from the very beginning of my interest in this company. Judging by way of the multiples of a huge number of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a classic battleground, or even some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *